Trial Profile
Allogeneic Stem Cell Transplantation of NiCord, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 28 Apr 2022
Price :
$35
*
At a glance
- Drugs Cord blood stem cell therapy (Primary)
- Indications Sickle cell anaemia; Thalassaemia
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Gamida-Cell
- 31 Mar 2022 Status changed from active, no longer recruiting to completed.
- 03 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 11 Apr 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Sep 2019.